E. Ohman J:or Asset Management 13F: Cuts AMGN Stake by $2.5M
Key Points
- E. Ohman J:or Asset Management cut its stake in Amgen Inc. by 30.7% during the third quarter, reducing its position to 13,532 shares worth about $5.7 million.
- Amgen Inc. recently posted trailing twelve-month revenue of $38.1 billion alongside a net margin of 23.0% and return on equity of 91.5%.
- Other large institutional investors like Nisa Investment Advisors and Wells Fargo & Company adjusted their own stakes in the healthcare firm recently.
Get Amgen text alerts
We text you when insiders, Congress, analysts or big funds move on $AMGN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Amgen Inc. alert may contain errors. Disclosures
E. Ohman J:or Asset Management cut its stake in Amgen Inc. (NasdaqGS: AMGN) by 30.7%, selling 5,983 shares during the period. The fund revealed the move in a Form 13F filed with the Securities and Exchange Commission on October 22, 2026.
AMGN
Amgen Inc.
E. Ohman J:or Asset Management vs. the S&P 500
Hypothetical returns from E. Ohman J:or Asset Management's disclosed trades, not real profit or advice. How we model this.
What Changed in E. Ohman J:or Asset Management's Amgen Position
The asset manager trimmed its holdings to 13,532 shares total. That remaining stake had a reported value of $5,703,873 at the time of the filing. Prior to this adjustment, the fund held 19,515 shares.
Other Institutional Activity in Amgen
Nisa Investment Advisors grew its holdings by 8,294 shares, ending with 167,256 shares worth about $70,500,076. Wells Fargo & Company held 7,235,462 shares valued at approximately $3,236,277,434 after increasing its position by 147,431 shares, or 2.1%.
Amgen Inc. Stock Up 1.9%
Amgen shares closed at $447.28 on October 22, 2026, and recently traded around $447.39 as of October 23, 2026. The stock sits near its 52-week high of $447.03, well above its 50-day moving average of $416.21 and its 200-day moving average of $370.53.
Recent Earnings
Amgen reported trailing twelve-month revenue of $38.1 billion. The drug manufacturer posted an earnings per share figure of $16.10, backed by a net profit margin of 23.0% and a return on equity of 91.5%. The company's next earnings update is scheduled for November 3, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 6.1%. Revenue missed estimates by 1.5%.
-
Profit surprise
EBITDA missed by 45 percent. Operating income missed by 28 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin up 4.6 points. Operating margin up 16.5 points. Positive free cash flow.
Earnings Call Summary
Amgen had a strong first quarter with earnings per share of 5.15 dollars beating expectations of 4.73 dollars. Six key medicines grew sales by 24 percent year over year and now make up 70 percent of total sales. The obesity drug Meritide is advancing well in late-stage testing with new studies showing better tolerance when patients take it less frequently, potentially every eight to twelve weeks instead of weekly injections.
Guidance Amgen raised its 2026 outlook to revenue between 37.1 billion and 38.5 billion dollars, and earnings per share between 21.70 and 23.10 dollars. The company expects its fast-growing medicines like Repatha and Evenity to offset patent losses. Management said capital spending will remain at about 2.6 billion dollars to scale manufacturing for new drug launches.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Amgen pays an annual dividend rate of $10.08 per share. This translates to a dividend yield of 2.3% and a payout ratio of 60.9%.
Insider Buying and Selling at Amgen Inc.
Company insiders completed several transactions prior to the filing. Officer Nancy A. Grygiel sold 2,970 shares on August 6, 2026, at an average price of $402.16. Officer Derek Miller sold 3,890 shares on the same day at $402.54 per share. Officer Rachna Khosla also sold 3,252 shares on August 13, 2026.
Analysts Set New Price Targets
Wall street research firms have updated their outlooks on the stock recently. UBS maintains a buy rating with a target price of $470.00. BMO Capital maintains a market perform rating with a $415.00 target. Wells Fargo maintains an equal-weight rating with a $430.00 target. Guggenheim maintains a neutral rating with a $378.00 target. Barclays maintains an equal-weight rating with a $400.00 target. Overall, the stock carries a hold consensus rating from 29 analysts with a mean target price of $395.67.
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Headquartered in Thousand Oaks, California, the company focuses on treatments for serious illnesses across several major healthcare categories.
Bottom Line
Investors tracking Amgen will look toward the upcoming November earnings report for fresh financial details. Institutional shifts and ongoing insider trades continue to draw market attention as the stock trades near its 52-week high.
Related Filing Alerts
Source: E. Ohman J:or Asset Management's 13F filing on $AMGN (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts